No Extra Liver Cancer Risk with Interferon-Free HCV Regimens

Monday, March 26, 2018

No Extra Liver Cancer Risk with Interferon-Free HCV Regimens

No Extra Liver Cancer Risk with Interferon-Free HCV Regimens

by Diana Swift, March 25, 2018

Earlier suggestions not supported in retrospective study of 857 patients

Successful treatment of cirrhotic patients with hepatitis C virus (HCV) with direct-acting interferon (IFN)-free antiviral therapy did not increase the risk of incident hepatocellular carcinoma (HCC), researchers said, nor was it associated with increased nodule size or number in those diagnosed with HCC.

According to a Scottish study published in the Journal of Hepatology, the elevated risk suggested by previous research was attenuated after accounting for differing characteristics between patients given regimens with or without interferon.
Continue reading: https://www.medpagetoday.com/gastroenterology/hepatitis/71969

Resource Link

Liver Cancer After Treatment For Hepatitis C
This page offers an index of links to current data investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during and after direct-acting antiviral therapy in patients with hepatitis C.

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.